/, Type 2 Diabetes/Lysulin® Hits the Market: A Breakthrough Dietary Supplement for People with Type 2 Diabetes and Prediabetes
Lysulin type 2 diabetes

Lysulin® Hits the Market: A Breakthrough Dietary Supplement for People with Type 2 Diabetes and Prediabetes

San Diego, CA (November 12, 2018) - Lysulin, Inc. announced today the launch of Lysulin®, a first-in-class nutritional supplement formulated for people with Type 2 diabetes and prediabetes.*

Read More

Lysulin® Hits the Market: A Breakthrough Dietary Supplement for People with Type 2 Diabetes and Prediabetes

San Diego, CA (November 12, 2018) – Lysulin, Inc. announced today the launch of Lysulin®, a first-in-class nutritional supplement formulated for people with Type 2 diabetes and prediabetes.* Lysulin provides a breakthrough, clinically studied approach for goal-oriented blood glucose management in an all-natural product available over-the-counter, without a prescription*.

Lysulin’s unique, patent-pending formulation contains three carefully balanced essential nutrients: Lysine, Zinc and Vitamin C, which in over 20 years of independent research have been shown to lower blood glucose and Hemoglobin A1c (A1c) levels, while improving the lipid profile.1* Lysulin acts as a personal guardian, shielding human proteins from glucose toxicity. In recent double-blind placebo controlled clinical studies, substantial reductions in A1c test levels were observed in people taking Lysulin as compared to people taking a placebo.

Glucose in the blood attaches to proteins in the body, changing the protein’s structure and affecting how these proteins function. This destructive process is called protein glycation, which many experts believe is the main cause of insulin resistance and diabetes complications such as blindness, kidney damage, and nerve damage, among others. Hemoglobin A1c (A1c) is a glycated protein, and because A1c levels measure the average blood glucose over the prior three months, physicians use the A1c test to measure the effectiveness of diabetes therapy. A 1% reduction in A1c reduces diabetes related deaths by 21%, risk of microvascular complications by 37% and myocardial infarction by 14%.2,3 Maintaining healthy A1c levels significantly reduces the risk of serious, long-term complications of Type 2 diabetes and because of this, Lysulin, Inc. also offers an easy to use, FDA approved, “At Home A1c Test”. People are encouraged to test their A1c levels prior to starting Lysulin and then test themselves again, after a month of taking Lysulin, so that they can see for themselves how Lysulin is working for them.

“Lysulin is delivering remarkable results in nutritional support for people concerned with diabetes,” said Dr. John F. Burd, Ph.D. and CEO of Lysulin, Inc. “Nutrition is a critical component of diabetes management and prevention and we are committed to delivering the most innovative formulation, backed by science, to help support a proactive approach to diabetic-related health.” With over 30 years of experience in glucose
monitoring technology, Dr. Burd was founder and CEO of Dexcom and is renowned for his work in the medical and biotechnology field. He was inducted into the American Association of Clinical Chemistry (AACC) Hall of Fame in 2005 after winning the Ullman prize for innovation in clinical chemistry.

Lysulin’s easy-to-take, chewable tablet is gluten free, vegetarian and vegan. Lysulin is available without a prescription and can be purchased at www.lysulin.com. For accompanying information for this press release and for further details about Lysulin, visit Lysulin.com.

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent disease.

1. Diabetes Manag (2018) 8(2), 038–40. Lysulin™, a new supplement for Nutritional Support for People with Diabetes and Pre-diabetes (those at risk of developing diabetes).
2. Br Med J 2000; 321:405-412.
3. Diabetologia (1993) 36: 797-801.

# # #

Media Contact:
GG Benitez
GG Benitez & Associates PR
Email: gg@ggbenitezpr.com
Phone: 619-339-7978

Download Press Release.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.